Literature DB >> 17070874

Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings.

María Sitges1, Luz María Chiu, Araceli Guarneros, Vladimir Nekrassov.   

Abstract

Several of the most effective antiepileptic drugs are believed to stop the paroxysmal neuronal activity acting as Na(+) channel blockers. However, no single study comparing in parallel the potency and efficacy of the most commonly used antiepileptic drugs on brain Na(+) channel-mediated responses is available. In the present study the effects of increasing concentrations of carbamazepine, phenytoin, lamotrigine, oxcarbazepine and topiramate, which are among the most frequently used antiepileptic drugs, and of the new putative antiepileptic drug, vinpocetine, on the release of glutamate (Glu) elicited by the Na(+) channel opener, veratridine were investigated in hippocampal isolated nerve endings preloaded with the labeled excitatory amino acid neurotransmitter. The present results show that carbamazepine, phenytoin, lamotrigine and oxcarbazepine, in the range from 150 to 1500 microM, progressively inhibit [(3)H]Glu release induced by veratridine. Also vinpocetine progressively inhibits the veratridine-induced response, but in a much lower range of concentrations (from 1.5 to 15 microM), whereas topiramate only exerts a modest inhibition (20%) of Glu release to veratridine at the highest dose tested (1500 microM). These results indicate that the mechanism of action of several of the most widely used antiepileptic drugs involves reduction in cerebral presynaptic voltage sensitive Na(+) channels permeability. Considering that the high doses of antiepileptic drugs required to control seizures are frequently accompanied by adverse secondary effects, the higher potency of vinpocetine to reduce Na(+) channels permeability might be advantageous.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070874     DOI: 10.1016/j.neuropharm.2006.09.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  25 in total

1.  A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence.

Authors:  E Sherwood Brown; Prabha Sunderajan; Lisa T Hu; Sharon M Sowell; Thomas J Carmody
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder.

Authors:  Epolia Ramadan; Mireille Basselin; Jagadeesh S Rao; Lisa Chang; Mei Chen; Kaizong Ma; Stanley I Rapoport
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

3.  Glutamatergic system abnormalities in posttraumatic stress disorder.

Authors:  Daisuke Nishi; Kenji Hashimoto; Hiroko Noguchi; Kei Hamazaki; Tomohito Hamazaki; Yutaka Matsuoka
Journal:  Psychopharmacology (Berl)       Date:  2015-08-22       Impact factor: 4.530

4.  Effects of antiepileptic drugs on glutamate release from rat and human neocortical synaptosomes.

Authors:  M Kammerer; B Brawek; T M Freiman; R Jackisch; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-30       Impact factor: 3.000

5.  Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder.

Authors:  Mani N Pavuluri; Alessandra M Passarotti; Erin M Harral; John A Sweeney
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

6.  Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

Authors:  David R Witty; Giuseppe Alvaro; Dominique Derjean; Gerard M P Giblin; Kevin Gunn; Charles Large; David T Macpherson; Valerie Morisset; Davina Owen; Joanne Palmer; Francois Rugiero; Simon Tate; Christopher A Hinckley; Himanshu Naik
Journal:  ACS Med Chem Lett       Date:  2020-07-16       Impact factor: 4.345

Review 7.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 8.  Topiramate: a review of its use in the treatment of epilepsy.

Authors:  Katherine A Lyseng-Williamson; Lily P H Yang
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Attenuation of the effects of corticosteroids on declarative memory with lamotrigine.

Authors:  E Sherwood Brown; Justin Wolfshohl; Mujeeb U Shad; Miguel Vazquez; I Julian Osuji
Journal:  Neuropsychopharmacology       Date:  2007-11-14       Impact factor: 7.853

10.  Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures.

Authors:  K Albus; A Wahab; U Heinemann
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.